Fig. 3: FOXM1 represses BMF gene expression during mitosis to prevent anoikis.
From: FOXM1 repression increases mitotic death upon antimitotic chemotherapy through BMF upregulation
a BMF and FOXM1 transcript levels in asynchronous (untreated, unt) and mitotic neonatal HDFs (shake-off upon STLC or TX treatment). b BMF and FOXM1 transcript levels in asynchronous (unt) and mitotic MCF-7 cells (shake-off upon STLC or TX treatment). c BMF and FOXM1 transcript levels in asynchronous (unt) and mitotic (shake-off upon STLC) MCF-7 cells depleted with Neg or FOXM1 siRNAs. d Experimental layout for the assessment of anoikis sensitivity in asynchronous (untreated) vs. mitotic-enriched (STLC treatment) MCF-7 cells cultured in poly-HEMA-coated flasks. e BMF transcript levels in the cell culture conditions depicted in d. f Annexin V/apoptosis cytometry analysis in the cell culture conditions depicted in d. g Annexin V cytometry analysis in the cell culture conditions depicted in d, using CRISPR/Cas9-edited control (Cas9) or BMF (BMF KO) MCF-7 cells. h Annexin V cytometry analysis in the cell culture conditions depicted in d, using MCF-7 cells lentiviral-transduced with empty or pLVX-BMF (BMF OX) plasmids. Data information: in a, b data are mean ± S.D. from n = 5 and n = 3 independent experiments; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 (two-tailed one-way ANOVA and Dunnett’s multiple comparison test). In c, e–h data are mean ± S.D. from n = 3 or n = 4 independent experiments; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (two-tailed one-way ANOVA and Tukey’s multiple comparison test).
